Methamphetamine produces subsequent reductions in running time to exhaustion in mice.
Treatment with methamphetamine (MA - 20 mg/kg x 4 i.p. at 2-h intervals) or its vehicle at 7 days prior to tests of running time to exhaustion were evaluated in 60-day-old CD-1 male mice. Pre-treatment running times were not significantly different between the two groups. MA resulted in significantly decreased running times to exhaustion compared to vehicle-treated controls and a significant reduction in corpus striatal dopamine and DOPAC but not norepinephrine. No statistically significant differences in catecholamines were obtained within the hypothalamus, or left ventricle of the heart, nor were body weights significantly different between these groups. The data show that a regimen of MA, which results in an approximate 90% depletion of striatal DA, produces a reduction in running time to exhaustion.
Kalinski
M I
MI
Exercise Sciences Laboratories, School of Exercise, Leisure and Sport, Kent State University, P.O. Box 5190, Kent, OH 44242-0001, USA. mkalinsk@kent.edu
Dluzen
D E
DE
Stadulis
R
R
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D004298:Dopamine / Q000172:deficiency*; D018765:Dopamine Uptake Inhibitors / Q000633:toxicity*; D005221:Fatigue / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000633:toxicity*; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D017072:Neostriatum / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D009434:Neural Pathways / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D009638:Norepinephrine / Q000378:metabolism; D010805:Physical Conditioning, Animal / Q000379:methods; D013378:Substantia Nigra / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology
D018765:Dopamine Uptake Inhibitors; D015102:3,4-Dihydroxyphenylacetic Acid; D008694:Methamphetamine; D004298:Dopamine; D009638:Norepinephrine